A Phase 4 interventional study of peginterferon beta-1a and brimonidine tartrate in Relapsing-Remitting Multiple Sclerosis (RRMS), sponsored by Biogen. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-25.
Sponsored by Biogen · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen — none open to participants now, 1 under way, 1 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Biogen.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 55th largest by enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2016, is one of 21 in phase 4, and was the 58th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 152 across the 59 interventional studies, 277 across the 19 observational. Of the 72 that completed or were terminated, 31 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
1 of the studies in Multiple Sclerosis, Relapsing-Remitting by Biogen that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03958877Phase 3BiogenA Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | 2027-05-20 |
Add it to your calendar (.ics) → With an account.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo).
The secondary study objectives are to evaluate the IRE mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel on a more stringent definition scale, in accordance with the primary endpoint of the original brimonidine pivotal trials and participants' satisfaction with the overall appearance of their skin.
Participants naïve to treatment with subcutaneous (SC) interferons or oral Disease Modifying Therapy (DMT) who are about to start PLEGRIDY PEN therapy will be screened for participation in this Phase IV trial. Participants will remain on Plegridy therapy as prescribed by their physician. Plegridy will not be provided to participants by Biogen as a part of this study.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will apply gel to injection site erythema area after IRE development post peginterferon beta-1a injection
Drug: peginterferon beta-1a · Drug: brimonidine tartrate
Participants will apply vehicle gel placebo to injection site erythema area after IRE development post peginterferon beta-1a injection
Drug: peginterferon beta-1a · Drug: Vehicle Gel
SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
Also known as: PEGylated Interferon Beta-1a, PEG IFN β-1a, Plegridy, BIIB017
Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
Also known as: Mirvaso
Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
Change in either Clinician's Erythema Assessment (CEA) or Patient Erythema Self-Assessment (PSA) scale measured as at least 1-grade improvement on CEA and/or at least 1-grade improvement on PSA scale assessed by the physician and participant
Investigator will evaluate participant's erythema (redness) at the site of injection on a scale of 0 (clear) to 4 (severe) with higher scores indicating higher levels of erythema. Participants rate erythema at the site of injection on a scale of 0 (clear) to 4 (severe) with higher scores indicating higher levels of erythema.
Time frame: Before and after 6 hours of gel application
Composite change in both CEA and PSA scale measured as at least 1-grade improvement on CEA and 1-grade improvement on PSA respectively
This composite endpoint is considered to be sensitive enough and directly correlated with participants' satisfaction therapy outcomes.
Time frame: Before and after 6 hours of gel application
Composite change in both CEA and PSA scale measured as at least 2-grade improvement on CEA and 2-grade improvement on PSA
Time frame: Before and after 6 hours of gel application
Participant's self-assessment of satisfaction with the overall appearance of their skin by using a Patient's Assessment of Appearance (PAA) grading scale
PAA satisfaction score will describe how satisfied the participants are with the overall appearance of skin on a scale of 0 (very satisfied) to 4 (very dissatisfied).
Time frame: Before and after 6 hours of gel application
No study locations are listed for this record.
The record gives a start of Feb 2016, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine
Multiple Sclerosis, Relapsing-Remitting →